30 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
encephalitis • Mycobacterium ... • Disseminated Mycobacterium ... • Hepatitis A virus ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
encephalitis • Mycobacterium ... • Disseminated Mycobacterium ... • Hepatitis A virus ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Species: • Mycobacterium ... characteristic features Clinical ... Tuberculosis Treatment ... Initiating Treatment ... Diagnosis #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Species: • Mycobacterium ... characteristic features Clinical ... Tuberculosis Treatment ... Initiating Treatment ... Diagnosis #Management #Treatment
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Preventing and Treating ... HIV-AIDS Preventing Clinical ... and preventing clinical ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Preventing and Treating ... Preferred Therapy for Treating ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Preventing and Treating ... Treating Acute Infection ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Recommendations for Treating ... every 21 days Treating ... Leishmaniasis #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Herpes Simplex Virus ... • Continue treatment ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Recommendations for Treating ... for effective treatment ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology